SUNNYVALE, Calif., Jan. 21, 2025 /PRNewswire/ -- Inflammatix, a pioneering host response diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing ...

SUNNYVALE, Calif., Nov. 28, 2023 /PRNewswire/ -- Inflammatix, Inc., a pioneering molecular diagnostics company, announced today that the US Food and Drug Administration (FDA) has granted Breakthrough ...

Just a few weeks later than expected, Inflammatix Inc. secured U.S. FDA clearance of the Triverity test system for use in emergency triage of patients with suspected acute infection or sepsis. The ...

Molecular diagnostics company Inflammatix has closed a $57 million funding round, which will support the company's plans for regulatory filing with the FDA and early commercialization of its flagship ...

Company Reaches Important Product Development Milestone with its Myrna™ Instrument and TriVerity Cartridge SUNNYVALE, Calif., Nov. 15, 2023 /PRNewswire/ -- Inflammatix, Inc., a pioneering molecular ...

SUNNYVALE, Calif., Oct. 1, 2024 /PRNewswire/ -- Inflammatix, a pioneering molecular diagnostics company, today presented data demonstrating the high diagnostic and prognostic accuracy of the company's ...

First Interventional Study Designed to Demonstrate the Clinical Utility of the TriVerity Test and its Impact on Patient Management "As the first interventional study to demonstrate the clinical ...

"The newly raised funds will help us to expand our commercial team and plan clinical interventional and health economic studies as we await FDA clearance over the coming months," said Dr. Timothy ...

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) purchases TriVerity Test System to evaluate for use in the field Inflammatix receives an ...

SUNNYVALE, Calif., Jan. 21, 2025 /PRNewswire/ -- Inflammatix, a pioneering host response diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing ...